Decision on intellectual property waiver over Covid technology on hold till 2021; what are...
Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer.
The...
Covid-19 intellectual property pool gaining support
While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...
The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless
Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...
High medicines prices in Europe – do not Brexit the people
The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...
New Database Documents the Power of TRIPS Flexibilities
Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS...
Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
Medicines Patent Pool signs first Covid-19 licence agreement with Merck Sharp & Dohme. Others...
The Medicines Patent Pool, a UN-backed organisation whose mission is to expand access to essential medicines around the world, today announced its first agreement...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...
Thank you for the opportunity to make a brief statement.
The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...
Faced with unreasonable medicines prices, the Netherlands introduces pharmacy exemption in patent law.
On 1 February 2019, article 53(3), second sentence of the Dutch Patent Act 1995 came into force introducing a patent exemption for the preparation...